Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Oct;13(5):216-223.
doi: 10.14740/jh1310. Epub 2024 Sep 16.

Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Histiocytic/Dendritic Cell Sarcoma

Affiliations
Case Reports

Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Histiocytic/Dendritic Cell Sarcoma

Jennifer Cai et al. J Hematol. 2024 Oct.

Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) transforming into a more aggressive lymphoma (i.e., Richter syndrome) is well documented in the literature. In recent years, transdifferentiation of CLL/SLL to histiocytic/dendritic/Langerhans cell sarcomas has also been reported. We hereby describe a case of a 55-year-old female who was incidentally diagnosed with CLL after presenting to the hospital for symptoms of undiagnosed rheumatoid arthritis. At the time of presentation, CLL was stage 1, and the patient was placed on observation. Eight years after being diagnosed with CLL, and after several treatment modalities for her rheumatoid arthritis, the patient re-presented with progression of adenopathy, intermittent fevers, 5-pound weight loss, and worsening respiratory status requiring airway management. Computed tomography (CT) imaging revealed a soft tissue mass in the nasopharynx, lingual tonsillar hypertrophy with airway compromise, and bulky cervical, supraclavicular, and axillary lymphadenopathy. A biopsy of an enlarged cervical lymph node yielded a diagnosis of histiocytic/dendritic cell sarcoma favoring interdigitating dendritic cell sarcoma, likely representing transdifferentiation from CLL/SLL, of which there are no standard of care treatment guidelines. The patient was treated with ifosfamide, carboplatin, and etoposide (ICE) for three cycles, followed by rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) in combination with zanubrutinib. She then underwent haploidentical hematopoietic stem cell transplantation. At the time of the making of this manuscript, the patient was 45 days post-transplant without any notable complications.

Keywords: Chronic lymphocytic leukemia; Histiocytic sarcoma; Histiocytic/dendritic cell sarcoma; Interdigitating dendritic cell sarcoma; Small lymphocytic leukemia; Transdifferentiation; Transformation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Photomicrograph of the ultrasound-guided core biopsy of an enlarged lymph node in the posterior triangle of the right neck shows lymphoid tissue with many paler areas. (H&E stain, original magnification, × 100). H&E: hematoxylin and eosin.
Figure 2
Figure 2
Photomicrographs of the ultrasound-guided core biopsy of an enlarged lymph node in the posterior triangle of the right neck. The paler areas contain sheets of atypical histiocytic/dendritic cells with irregular nuclear contours and prominent/distinct nucleoli. There are occasional mitotic figures, including atypical ones (a, short arrow). Small mature lymphocytes and scattered eosinophils (b, long arrows) are admixed (H&E stain, original magnification, (a) × 200, (b) × 400). H&E: hematoxylin and eosin.
Figure 3
Figure 3
Immunohistochemical (IHC) characterization of the tumor. The histiocytic/dendritic cells are positive for CD4 (a), CD45 (not shown), CD68 (granular and Golgi pattern (b), CD163 (small subset, not shown), BCL6 (c), cyclin D1 (d), lysozyme (e), and S-100 (f), weakly positive for OCT-2 (g) and BCL2 (subset, not shown), and were negative for CD1a (not shown), CD3 (not shown), CD5 (not shown), CD10 (not shown), CD20 (not shown), CD21 (not shown), CD23 (not shown), CD30 (not shown), CD79a (not shown), ALK1 (not shown), BOB.1 (h), MUM1 (not shown), PAX-5 (not shown), and cytokeratin AE1/AE3 (not shown). (i) Ki67 IHC stain shows a high proliferation rate (immunoperoxidase staining; original magnification, × 200).
Figure 4
Figure 4
A small focus of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) by immunohistochemistry. The CLL/SLL cells are negative for CD3 (a), but express CD5 (b), CD20 (c), and CD23 (d). The background T-lymphocytes are positive for both CD3 and CD5 (immunoperoxidase staining; original magnification, × 200). CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma.

Similar articles

Cited by

References

    1. Kommalapati A, Tella SH, Durkin M, Go RS, Goyal G. Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood. 2018;131(2):265–268. doi: 10.1182/blood-2017-10-812495. - DOI - PMC - PubMed
    1. Shao H, Xi L, Raffeld M, Feldman AL, Ketterling RP, Knudson R, Rodriguez-Canales J. et al. Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Mod Pathol. 2011;24(11):1421–1432. doi: 10.1038/modpathol.2011.102. - DOI - PMC - PubMed
    1. Khashab T, Sehgal L, Medeiros LJ, Samaniego F. Spontaneous regression of interdigitating dendritic sarcoma in a patient with concurrent small lymphocytic lymphoma. BMJ Case Rep. 2015;2015:bcr2014209014. doi: 10.1136/bcr-2014-209014. - DOI - PMC - PubMed
    1. Castro D, Zhang LQ, Nandula S, Choe J, Cai D. Chronic lymphocytic leukemia transdifferentiates into neuroendocrine carcinoma: a case report of a new phenomenon. 2016. North American Journal of Medicine & Science.
    1. Ghia EM, Jain S, Widhopf GF 2nd, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG. et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008;111(10):5101–5108. doi: 10.1182/blood-2007-12-130229. - DOI - PMC - PubMed

Publication types